These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36545710)

  • 1. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
    Badar T; Litzow MR; Shallis RM; Patel A; Saliba AN; Burkart M; Bewersdorf JP; Stahl M; De Camargo Correia GS; Guru Murthy GS; Abaza Y; Duvall A; Bradshaw D; Kota V; Dinner S; Goldberg AD; Palmisiano N; Al Kali A; Atallah E
    Cancer; 2023 Mar; 129(6):934-945. PubMed ID: 36545710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.
    Abraham IE; Rauscher GH; Patel AA; Pearse WB; Rajakumar P; Burkart M; Aleem A; Dave A; Bharadwaj S; Paydary K; Acevedo-Mendez M; Goparaju K; Gomez R; Carlson K; Tsai SB; Quigley JG; Galvin JP; Zia M; Larson ML; Berg S; Stock W; Altman JK; Khan I
    Blood; 2022 Apr; 139(14):2212-2226. PubMed ID: 35061876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of race on outcomes in intermediate-risk acute myeloid leukemia.
    Abraham IE; Patel AA; Wang H; Galvin JP; Frankfurt O; Liu L; Khan I
    Cancer Causes Control; 2021 Jul; 32(7):705-712. PubMed ID: 33837498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.
    Carbajal-Ochoa WH; Johnson D; Alvarez A; Bernal AM; Anampa JD
    Breast Cancer Res Treat; 2023 Sep; 201(2):275-287. PubMed ID: 37442877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Disparities in Health Care Resource Utilization After Pediatric Cervical and/or Thoracic Spinal Injuries.
    Elsamadicy AA; Sandhu MR; Freedman IG; Koo AB; Hengartner AC; Reeves BC; Havlik J; Sarkozy M; Hong CS; Kundishora AJ; Tuason DA; DiLuna M
    World Neurosurg; 2021 Dec; 156():e307-e318. PubMed ID: 34560297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.
    Huang T; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
    Br J Haematol; 2023 Feb; 200(4):494-505. PubMed ID: 36345800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
    Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
    Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
    [No Abstract]   [Full Text] [Related]  

  • 9. Racial and Ethnic Disparities in Functional Outcome after Thrombectomy: A Cohort Study of an Integrated Stroke Network.
    Jones E; Kumar A; Lopez-Rivera V; Sebaugh J; Kamal H; Sheth SA; Sharrief A; Zha A
    J Stroke Cerebrovasc Dis; 2021 Dec; 30(12):106131. PubMed ID: 34655973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
    Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial Differences in Time to Breast Cancer Surgery and Overall Survival in the US Military Health System.
    Eaglehouse YL; Georg MW; Shriver CD; Zhu K
    JAMA Surg; 2019 Mar; 154(3):e185113. PubMed ID: 30673075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
    Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
    Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
    Ciftciler R; Demiroglu H; Buyukasık Y; Aladag E; Aksu S; Haznedaroglu IC; Sayınalp N; Ozcebe O; Malkan UY; Goker H
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):177-182. PubMed ID: 30616990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
    Vasudevan Nampoothiri R; Chen S; Pasic I; Al-Shaibani Z; Lam W; Michelis FV; Kim DDH; Viswabandya A; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Law AD
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):134-140. PubMed ID: 33049225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
    Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial disparities in survival among women with endometrial cancer in an equal access system.
    Park AB; Darcy KM; Tian C; Casablanca Y; Schinkel JK; Enewold L; McGlynn KA; Shriver CD; Zhu K
    Gynecol Oncol; 2021 Oct; 163(1):125-129. PubMed ID: 34325938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
    Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial and Ethnic Disparities in the Investigation and Treatment of Growth Hormone Deficiency.
    Hawkes CP; Gunturi H; Dauber A; Hirschhorn JN; Grimberg A
    J Pediatr; 2021 Sep; 236():238-245. PubMed ID: 33901521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.